Association between type II secretory phospholipase A 2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease

European Heart Journal

Volumn 30, Issue 22, 2009, Pages 2742-2748

  Koenig, Wolfgang ^a   Vossen, Carla Y ^b   Mallat, Ziad ^c   Brenner, Hermann ^b   Benessiano, Joëlle ^c   Rothenbacher, Dietrich ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Cohort study; Coronary heart disease; Inflammation; Pathomechanism; Prognosis; Type IIA secretory phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROMETRY; GROUP II PHOSPHOLIPASES A2; HUMANS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 72949102004     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp302     Document Type: Article

References (17)

1. 2 in vascular disease. Circ Res 2001;89:298-304.
2. 2 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 2000;20:1276-1282.
3. 2 and of lysophosphatidic acid synthesis. Adv Enzyme Regul 1998;38:99-107.
4. 2 expression in human aortic tissue in dependence on the degree of atherosclerosis. Atherosclerosis 1999;144:73-78.
5. 2 against Staphylococcus aureus. J Immunol 1999;162:7402-7408.
6. Weinrauch Y, Abad C, Liang NS, Lowry SF, Weiss J. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phos-pholipase A2. J Clin Invest 1998;102:633-638.
7. 2 modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999;274: 25913-25920.
8. 2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999; 19:1291-1298.
9. 2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population study. Arterioscler Thromb Vasc Biol 2005;25:839-846.
10. 2 activity and risk of incident coronary events in healthy men and women. The EPIC-NORFOLK study. Arterioscler Thromb Vasc Biol 2007;27: 1177-1183.
11. 2 predict coronary events in patients with coronary artery disease. Circulation 1999;100:1280-1284. (Pubitemid 29440119)
12. 2 in patients with unstable angina pectoris. Am J Cardiol 2000;86:718-722. (Pubitemid 30734924)
13. 2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005;46:1249-1257.
14. 2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824-1832.
15. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005;51:321-327. (Pubitemid 40175801)
16. Rothenbacher D, Koenig W, Brenner H. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 2006;166: 2455-2460.
17. 2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006;26: 1586-1593.